Dr. McKay on a Real-World Analysis of Radium-223 in mCRPC

Rana R. McKay, MD
Published: Wednesday, Feb 26, 2020



Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the results of a real-world analysis of radium-223 (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

The trial enrolled 220 patients with mCRPC who received at least 1 dose of radium-223 between 2013 and 2017 and did not have visceral metastases when radium-223 was started. Moreover, 63 patients received radium-223 prior to chemotherapy, 83 patients received radium-223 after chemotherapy, and 73 patients did not receive any chemotherapy.

Radium-223 is typically given intravenously every 4 weeks for up to 6 cycles. The mean number of injections patients received in the pre-chemotherapy group was 5.3 compared with 4.3 in the post-chemotherapy group. Additionally, patients in the pre- and post-chemotherapy cohorts received an average of 9.0 and 9.2 cycles of chemotherapy, respectively.

These findings suggest that administering radium-223 prior to chemotherapy is associated with an increased likelihood of completing the full course of treatment without limiting the administration of subsequent chemotherapy, concludes McKay.
SELECTED
LANGUAGE


Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the results of a real-world analysis of radium-223 (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

The trial enrolled 220 patients with mCRPC who received at least 1 dose of radium-223 between 2013 and 2017 and did not have visceral metastases when radium-223 was started. Moreover, 63 patients received radium-223 prior to chemotherapy, 83 patients received radium-223 after chemotherapy, and 73 patients did not receive any chemotherapy.

Radium-223 is typically given intravenously every 4 weeks for up to 6 cycles. The mean number of injections patients received in the pre-chemotherapy group was 5.3 compared with 4.3 in the post-chemotherapy group. Additionally, patients in the pre- and post-chemotherapy cohorts received an average of 9.0 and 9.2 cycles of chemotherapy, respectively.

These findings suggest that administering radium-223 prior to chemotherapy is associated with an increased likelihood of completing the full course of treatment without limiting the administration of subsequent chemotherapy, concludes McKay.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x